Should Shares CRISPR Therapeutics Be a February Pick?
Biotech investors chase game-changing tech, but CRISPR Therapeutics carries real regulatory milestones and execution ...
Why Active Funds May Underperform Benchmarks discusses persistent headwinds, costs, and timing issues that hinder outperformance.
26,804 articlesBiotech investors chase game-changing tech, but CRISPR Therapeutics carries real regulatory milestones and execution ...
As Madrigal prepares to report its 2025 earnings, investors weigh pipeline progress, cash runway, and milestones ahea...
A high-profile moment shows how a single statement can ripple into your wallet. This article breaks down the financia...
A Wayfair founder sold shares worth about $2.1 million in February 2026. This article breaks down what insider sellin...
A small exodus of California's billionaires ahead of a proposed wealth tax could erase billions in expected revenue. ...
With earnings on the horizon and a bold pivot to AI infrastructure, investors face a tough call. This guide breaks do...
Iran is creating a transit oversight agency to vet and tax vessels passing through the Strait of Hormuz, a developmen...
Discover what the (sfl) 2026 earnings call implies for revenue trends, balance sheet health, and the road ahead. This...
A May 14, 2026 filing shows Trump boosting crypto exposure by buying Coinbase and Bitcoin-related stocks, a notable m...
Investors are watching a growing wave of AI IPO chatter. If OpenAI opts for a confidential filing, understanding the ...
Cerebras hit the market with fireworks, then cooled off quickly. This guide explains what happened, how to value the ...
When a billionaire investor voices concern about Bitcoin, questions follow. This article digs into what the claim mig...